Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal mRNA Vaccine for Recurrent or Progressive High-grade Glioma
NCT07306299Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2025
- Primary completion
- Jan 2028
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mV002 in glioma, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Safety and tolerability of a mRNA vaccine. Started Dec 2025; status: recruiting.
02
Drugs
mV002
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07306299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07306299.